Use of stored serum in the study of time trends and geographical differences in exposure of pregnant women to phthalates

Louise S. Henriksen1, Barbara K. Mathiesen2, Maria Assens1, Marianna Krause3, Niels Erik Skakkebæk4, Anders Juul5, Anna-Maria Andersson6, Roger J. Hart5,6, John P. Newnham7, Jeffrey A. Keelan8, Craig Pennell9, Katharina M. Main10 and Hanne Frederiksen11

1 Department of Growth and Reproduction and EDMArc, Rigshospitalet, University of Copenhagen, Denmark. 2 Division of Obstetrics & Gynaecology, Faculty of Health & Medical Sciences, University of Western Australia, Australia. 3 Fertility Specialists of Western Australia, Bethesda Hospital, Australia. 4 Discipline of Obstetrics and Gynaecology, School of Medicine and Public Health, Faculty of Medicine and Health, The University of Newcastle, Australia

The authors have no conflicts of interest related to the presented data.

Key findings

- Serum phthalate metabolites may be used to assess prenatal exposure to some, but not all, phthalates if interpreted with caution.
- Phthalate exposure varies between countries and over time. European regulations appear to have resulted in decreasing exposure from the early 1990s to the 2010s in Denmark.

Background

Prenatal exposure to phthalates may have adverse health effects later in life. In the EU, the first temporary restrictions on phthalates were enacted in December 1999. These involved DEHP, BBP, DnBP as well as the use of DNP, DDP, DNOP specifically in toys and child care articles.

Historical birth cohorts with adult offspring often only have maternal serum samples to assess prenatal exposure. There are two main challenges with measurements in serum compared to urine:

- Lower phthalate metabolite levels due to fast metabolism in vivo
- Risk of post-collection contamination

We wished to explore:

A. Whether prenatal maternal serum samples can be used to assess phthalate exposure.
B. Differences in phthalate exposure across three birth cohorts from different geographical regions and times.

Methods

Population: Pregnant women in three birth cohorts

<table>
<thead>
<tr>
<th>Population</th>
<th>The Raine cohort</th>
<th>Cop1</th>
<th>Cop2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>1989-91</td>
<td>1997-2001</td>
<td>2012-14</td>
</tr>
<tr>
<td>n</td>
<td>986, GA = 18/34</td>
<td>235, GA = 23</td>
<td>103, GA = 18</td>
</tr>
</tbody>
</table>

Outcomes: 32 phthalate metabolites from 15 phthalate diesters measured by isotopodiluted liquid chromatography-tandem mass spectrometry (LC-MS/MS) in

- Serum samples from Raine and Cop1
- Urine and serum samples from Cop2

Statistics:

- Correlations were tested by Spearman’s test.
- Differences between the cohorts were tested by Mann-Whitney U test

Results & Discussion

A

Samples are at risk of being contaminated with phthalate diesters from the environment during sampling, handling and storage. Unlike urine, serum contains esterases that can catalyze the conversion of diesters to monoesters. Oxidation of diesters can only occur in vivo.

If samples have been contaminated, levels of primary diesters will generally be high and metabolite levels of primary and secondary metabolites will not correlate.

In our three cohorts, we found:

- Generally large inter-individual variation in serum phthalate levels.
- Significant correlations between primary and secondary metabolites in serum (r = 0.153-0.710, P < 0.01).

Further, we found significant correlations between some metabolite levels in serum and urine samples (Table 1).

Overall, these findings support that serum levels of some phthalate metabolites originate from true phthalate exposure.

B

Generally, serum phthalate metabolite concentrations and detection rates were higher in the Australian cohort compared to the two Danish cohorts. Levels in the older Danish cohort were overall higher than in the recent one which is congruent with regulations on phthalate-use in the EU since 1999.

- In Cop2, all phthalates were significantly lower than in the Raine cohort (P < 0.05) and, apart from MCiOP, also than in Cop1 (P < 0.001).
- In the Raine cohort, levels of MECPP, MCPP and MCiOP (P < 0.001) as well as MCMHP (P = 0.01) were significantly higher than in Cop1.
- Levels of MiBP, MIdP and MHMB were significantly higher (P < 0.001 in Cop1) in the Raine cohort.

![Figure 1 | Median maternal serum concentrations of selected phthalate metabolites (ng/mL)](image)

Table 1 | Correlations between selected serum and urine phthalate metabolite levels (ng/mL)

<table>
<thead>
<tr>
<th>Serum levels</th>
<th>MEP</th>
<th>MEHP</th>
<th>MECP</th>
<th>MEHP</th>
<th>MCPP</th>
<th>MCiOP</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEP</td>
<td>0.580***</td>
<td>0.080</td>
<td>0.031</td>
<td>0.032</td>
<td>0.039</td>
<td>-0.041</td>
</tr>
<tr>
<td>MEHP</td>
<td>0.221</td>
<td>0.151</td>
<td>0.183</td>
<td>0.160</td>
<td>0.034</td>
<td>-0.001</td>
</tr>
<tr>
<td>MECP</td>
<td>0.314***</td>
<td>0.343***</td>
<td>0.360***</td>
<td>0.359**</td>
<td>0.208</td>
<td>0.108</td>
</tr>
<tr>
<td>MEP</td>
<td>0.118</td>
<td>0.159</td>
<td>0.173</td>
<td>0.208</td>
<td>0.108</td>
<td>0.009</td>
</tr>
<tr>
<td>MCPP</td>
<td>0.231**</td>
<td>0.171</td>
<td>0.181</td>
<td>0.167</td>
<td>0.302**</td>
<td>0.246*</td>
</tr>
<tr>
<td>MEP</td>
<td>0.028</td>
<td>0.032</td>
<td>0.096</td>
<td>0.142</td>
<td>-0.008</td>
<td>0.010</td>
</tr>
<tr>
<td>MCiOP</td>
<td>0.060</td>
<td>0.083</td>
<td>0.089</td>
<td>0.222*</td>
<td>0.230*</td>
<td>0.296***</td>
</tr>
</tbody>
</table>

Significant correlations: *P < 0.05, **P < 0.01, ***P < 0.001.

Conclusion

- Historical biobank serum samples may be used for assessment of exposure to some, but not all, phthalates if interpreted with caution. Our data support that especially primary metabolites should be cautiously interpreted.
- Geographical regions seem to differ in phthalate exposure patterns, and European regulations appear to have resulted in a decreasing exposure from the early 1990s to the 2010s in Denmark. National/local production and consumer patterns also seem to affect exposure.